🔥🐔 BizChicken 🐔🔥

Companies Similar to Clene Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Clene Inc.

Clene Inc. logo
Market Cap: Lowest
Employees: Low

CNM-Au8

Clene Inc. is a clinical-stage pharmaceutical company that specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. Their leading drug, CNM-Au8, is involved in multiple clinical trials for treatments including amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease.

Tags: ALS, Clinical Trials, Multiple Sclerosis, Nanotechnology, Parkinson's Disease, Pharmaceuticals

Symbol: CLNN

Recent Price: $5.00

Industry: Biotechnology

CEO: Mr. Robert Etherington MBA

Sector: Healthcare

Employees: 82

Address: 6550 South Millrock Drive, Salt Lake City, UT 84121

Phone: 801 676 9695

Last updated: 2024-12-31

Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

Mino-Lok, Mino-Wrap, Halo-Lido, Nove Cite, I/ONTAK

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of critical care products, including anti-infective products, adjunct cancer care, prescription products, and stem cell therapy.

Tags: anti-infective, biotech, cancer care, critical care, pharmaceuticals, stem cell therapy

Symbol: CTXR

Recent Price: $3.91

Industry: Biotechnology

CEO: Mr. Leonard L. Mazur

Sector: Healthcare

Employees: 22

Address: 11 Commerce Drive, Cranford, NJ 07016

Phone: 908 967 6677

Leadership

  • Leonard Mazur, Co-Founder, CEO & Chairman of the Board of Director
  • Myron Holubiak, Co-Founder, Executive Vice Chairman
  • Jaime Bartushak, Chief Financial Officer & Chief Business Officer
  • Myron S. Czuczman, MD, Chief Medical Officer and EVP
  • Gary F. Talarico, EVP, Operations
  • Jay Wadekar, SVP, Business Strategy
  • Kelly Creighton, PhD, EVP, Chemistry, Manufacturing and Controls
  • Catherine Kessler, MS, EVP, Regulatory Affairs
  • Nikolas Burlew, EVP, Quality Assurance
  • Alan Lader, PhD, SVP, Head of Clinical Operations and Quality Assurance
  • Ilanit Allen, VP, Investor Relations
  • John Westman, VP, Project Management
  • Paul Sowyrda, VP, Business Development & Market Intelligence
  • Suren Dutia, Director
  • Eugene Holuka, MD, Director
  • Carol Webb, Director
  • Dennis M. McGrath, Director
  • Robert Smith, Director

Last updated: 2024-12-31

Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

REN001

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.

Tags: Clinical Trials, Genetic Disorders, Mitochondrial Diseases, Pharmaceuticals, Therapeutics

Symbol: RPHM

Recent Price: $18.20

Industry: Biotechnology

CEO: Mr. Gregory J. Flesher

Sector: Healthcare

Employees: 8

Address: 18575 Jamboree Road, Irvine, CA 92612

Phone: 619 733 3852

Last updated: 2024-12-31

Alto Neuroscience, Inc.

Alto Neuroscience, Inc. logo
Market Cap: Low
Employees: Low

ALTO-100, ALTO-300, ALTO-101, ALTO-203, ALTO-202

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company specializing in psychiatry drug development, with a range of innovative treatments targeting major depressive disorder and cognitive impairments.

Tags: AI-enabled biomarker, MDD, biopharmaceutical, cognitive impairment, drug development, psychiatry, schizophrenia

Symbol: ANRO

Recent Price: $4.20

Industry: Biotechnology

CEO: Dr. Amit Etkin M.D., Ph.D.

Sector: Healthcare

Employees: 78

Address: 369 South San Antonio Road, Los Altos, CA 94022

Phone: (650) 200-0412

Last updated: 2024-12-31

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

ACU193

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for Alzheimer's disease, with a key drug candidate ACU193 targeting amyloid-beta oligomers.

Tags: ACU193, Alzheimer's disease, biopharmaceutical, clinical-stage, immunotherapy

Symbol: ABOS

Recent Price: $1.75

Industry: Biotechnology

CEO: Mr. Daniel J. O'Connell M.B.A.

Sector: Healthcare

Employees: 51

Address: 427 Park Street, Charlottesville, VA 22902

Phone: 434 297 1000

Last updated: 2024-12-31

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Zunsemetinib

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases. It operates through Therapeutics and Contract Research segments, addressing unmet needs with innovative therapies, including treatments for rheumatoid and psoriatic arthritis, atopic dermatitis, autoimmune diseases, inflammatory bowel disease, and certain cancers.

Tags: atopic dermatitis, autoimmune diseases, biopharmaceutical, cancer, contract research, drug development, immune-inflammatory diseases, psoriatic arthritis, rheumatoid arthritis, therapeutics

Symbol: ACRS

Recent Price: $2.48

Industry: Medical - Diagnostics & Research

CEO: Dr. Neal S. Walker D.O., M.D.

Sector: Healthcare

Employees: 86

Address: 640 Lee Road, Wayne, PA 19087

Phone: 484 324 7933

Last updated: 2024-12-31

Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

AD04

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for addiction and related disorders. Its lead product, AD04, is in Phase III clinical trial for alcohol use disorder treatment.

Tags: AD04, addiction treatment, alcohol use disorder, biopharmaceutical, clinical trials

Symbol: ADIL

Recent Price: $1.03

Industry: Biotechnology

CEO: Mr. Cary John Claiborne MBA

Sector: Healthcare

Employees: 4

Address: 1180 Seminole Trail, Charlottesville, VA 22901

Phone: 434 422 9800

Last updated: 2024-12-31

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. logo
Market Cap: Low
Employees: Low

ALX148

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company developing therapies for cancer patients. Its lead product, ALX148, targets CD47 and is in trials for various cancers. The company also explores pre-clinical treatments like ALTA-002 to enhance immune response to cancer.

Tags: CD47, cancer therapy, clinical trials, collaboration, immuno-oncology, solid tumors

Symbol: ALXO

Recent Price: $1.66

Industry: Biotechnology

CEO: Mr. Jason W. Lettmann

Sector: Healthcare

Employees: 81

Address: 323 Allerton Avenue, South San Francisco, CA 94080

Phone: 650 466 7125

Last updated: 2024-12-31

BioVie Inc.

BioVie Inc. logo
Market Cap: Lowest
Employees: Lowest

BIV201, NE3107

Bio Vie Inc., a clinical stage biotechnology company, focuses on discovering, developing, and commercializing drug therapies in the United States, with products targeting liver cirrhosis, Alzheimer's, Parkinson's, multiple myeloma, and prostate cancer.

Tags: Alzheimer's, Biotechnology, Clinical Trials, Drug Development, Liver Cirrhosis, Parkinson's, Pharmaceutical

Symbol: BIVI

Recent Price: $2.09

Industry: Biotechnology

CEO: Mr. Cuong Viet Do M.B.A.

Sector: Healthcare

Employees: 14

Address: 680 West Nye Lane, Carson City, NV 89703

Phone: 775 888 3162

Last updated: 2024-12-31

C4 Therapeutics, Inc.

C4 Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

CFT7455

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Their lead product candidate, CFT7455, targets multiple myeloma and non-Hodgkin lymphomas.

Tags: biopharmaceutical, cancer treatment, clinical-stage, neurodegenerative diseases, protein degradation, therapeutics

Symbol: CCCC

Recent Price: $3.64

Industry: Biotechnology

CEO: Mr. Andrew J. Hirsch M.B.A.

Sector: Healthcare

Employees: 145

Address: 490 Arsenal Way, Watertown, MA 02472

Phone: 617 231 0700

Leadership

  • Kendra Adams, Chief Financial Officer
  • Scott Boyle, Ph.D., Chief Business Officer
  • Stew Fisher, Ph.D., Chief Scientific Officer
  • Len Reyno, M.D., Chief Medical Officer
  • Jolie Siegel, Chief Legal Officer
  • Kelly Schick, Chief People Officer
  • Mary Christian, Pharm. D., Senior Vice President, Regulatory
  • Mayra Reyes-Armour, Ph.D., Senior Vice President, Technical Operations, Quality and Facilities
  • Ron Cooper, Chairman
  • Ken Anderson, M.D., Director
  • Laura Bessen, M.D., Director
  • Bruce Downey, Director
  • Stephen Fawell, Ph.D., Director
  • Donna Grogan, M.D., Director
  • Andrew Hirsch, President and Chief Executive Officer, Director
  • Owen Hughes, Director
  • Utpal Koppikar, Director
  • Marc Cohen, In MemoriamCo-Founder & Executive Chairman Emeritus

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Cingulate Inc.

Cingulate Inc. logo
Market Cap: Lowest
Employees: Lowest

CTx-1301

Cingulate Inc. is focused on developing product candidates for treating attention-deficit/hyperactivity disorder (ADHD) and anxiety disorders. Its pipeline includes CTx-1301 and CTx-1302 for ADHD, and CTx-2103 for anxiety.

Tags: ADHD, anxiety disorders, biopharmaceutical, clinical trials

Symbol: CING

Recent Price: $4.98

Industry: Biotechnology

CEO: Dr. Shane J. Schaffer Pharm.D.

Sector: Healthcare

Employees: 13

Address: 1901 West 47th Place, Kansas City, KS 66205

Phone: 913 942 2300

Leadership

  • Shane J. Schaffer, PharmD, Chairman, Chief Executive Officer
  • Peter J. Werth, Director
  • Jeff Ervin, Director
  • Bryan Lawrence, Director
  • Jay Roberts, Director

Last updated: 2024-12-31

Moleculin Biotech, Inc.

Moleculin Biotech, Inc. logo
Market Cap: Lowest
Employees: Lowest

Annamycin

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company developing drug candidates for highly resistant tumors and viruses. Its lead product, Annamycin, is in Phase 1/2 studies, and it also works on other candidates targeting brain tumors, pancreatic cancer, and COVID-19.

Tags: Biotech, Cancer treatment, Clinical-stage, Drug development, Pharmaceutical, Phase 1/2 studies

Symbol: MBRX

Recent Price: $1.79

Industry: Biotechnology

CEO: Mr. Walter V. Klemp

Sector: Healthcare

Employees: 18

Address: 5300 Memorial Drive, Houston, TX 77007

Phone: 713 300 5160

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Nuvalent, Inc.

Nuvalent, Inc. logo
Market Cap: Highest
Employees: Low

NVL-520 and NVL-655

Nuvalent, Inc. is a clinical stage biopharmaceutical company that develops therapies for patients with cancer, focusing on brain-penetrant inhibitors for ROS1 and ALK.

Tags: ALK inhibitor, ROS1 inhibitor, biopharmaceutical, cancer therapies, clinical trials

Symbol: NUVL

Recent Price: $77.87

Industry: Biotechnology

CEO: Dr. James R. Porter Ph.D.

Sector: Healthcare

Employees: 115

Address: One Broadway, Cambridge, MA 02142

Phone: 857 357 7000

Last updated: 2024-12-31

Avanos Medical, Inc.

Avanos Medical, Inc. logo
Market Cap: Medium
Employees: High

Mic-Key, Corpak, Neo Med, Ballard, Microcuff, Endoclear, On-Q, amb IT, Game Ready, Coolief

Avanos Medical, Inc. is a medical technology company focused on delivering medical device solutions globally. They offer chronic care products in digestive and respiratory health, and non-opioid pain solutions.

Tags: chronic care, digestive health, medical technology, non-opioid pain solutions, respiratory health

Symbol: AVNS

Recent Price: $15.58

Industry: Medical - Devices

CEO: Mr. Michael C. Greiner

Sector: Healthcare

Employees: 3771

Address: 5405 Windward Parkway, Alpharetta, GA 30004

Phone: 844 428 2667

Last updated: 2024-12-31

Axonics, Inc.

Axonics, Inc. logo
Market Cap: High
Employees: Medium

SNM System, Bulkamid

Axonics, Inc. is a medical technology company focused on the development and commercialization of sacral neuromodulation systems for treating overactive bladder, urinary incontinence, and other related conditions, and offers Bulkamid for female stress urinary incontinence. It operates in the U.S., U.K., Germany, the Netherlands, Nordic countries, and internationally.

Tags: Bulkamid, Healthcare, Medical Technology, Overactive Bladder, Rechargeable SNM System, Sacral Neuromodulation, Urinary Incontinence

Symbol: AXNX

Recent Price: $70.98

Industry: Medical - Devices

CEO: Mr. Raymond W. Cohen

Sector: Healthcare

Employees: 797

Address: 26 Technology Drive, Irvine, CA 92618

Phone: 949 396 6322

Last updated: 2024-12-31

Cullinan Oncology, Inc.

Cullinan Oncology, Inc. logo
Market Cap: Medium
Employees: Low

CLN-081

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Their lead candidate, CLN-081, is in a trial for treating non-small cell lung cancer. The company also has several preclinical products targeting various forms of cancer.

Tags: biopharmaceutical, cancer, clinical trials, immuno-oncology, oncology, therapies

Symbol: CGEM

Recent Price: $12.20

Industry: Biotechnology

CEO: Mr. Nadim Ahmed

Sector: Healthcare

Employees: 85

Address: One Main Street, Cambridge, MA 02142

Phone: 617 410 4650

Last updated: 2024-12-31

IN8bio, Inc.

IN8bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

INB-200, INB-100, INB-400, INB-300

IN8bio, Inc. is a clinical-stage biotechnology company focused on gamma-delta T cell therapies for cancer treatment, with lead products in clinical trials and preclinical development.

Tags: biopharmaceutical, biotechnology, cancer treatment, clinical trials, gamma-delta T cell therapies

Symbol: INAB

Recent Price: $0.27

Industry: Biotechnology

CEO: Mr. Tai-Wei Ho

Sector: Healthcare

Employees: 39

Address: 350 5th Avenue, New York, NY 10118

Phone: 646 600 6438

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31